Today is June 02, 2024. All times in Eastern Daylight Time.
CatalYm Reports Impressive and Lasting Responses Including Multiple Complete Responses in Heavily Pretreated, Late- to Last-Line Metastatic NSCLC, Urothelial and Hepatocellular Cancer Patients Treated with Visugromab/Nivolumab Combination
06/02/2024 - 12:30 PM
BUSINESS WIRE
Stronger Than Ever: Adani Portfolio Delivers Record Performance
06/02/2024 - 12:09 PM
BUSINESS WIRE
Belantamab Mafodotin combination reduced the risk of disease progression or death by nearly 50% versus standard of care combination in relapsed/refractory multiple myeloma
06/02/2024 - 10:56 AM
BUSINESS WIRE
Puma Biotechnology Announces Presentation of Findings from a Phase II Study of Alisertib in Endocrine-Resistant Metastatic Breast Cancer (TBCRC 041)
06/02/2024 - 10:01 AM
BUSINESS WIRE
Tempus Introduces New HER2 & FOLR1 Testing Solutions to Support Personalized Patient Care
06/02/2024 - 09:30 AM
BUSINESS WIRE
ZT Systems Announces ACX200 Solutions Featuring NVIDIA GB200 Grace Blackwell Superchips for Next-Generation Accelerated Computing
06/02/2024 - 09:00 AM
BUSINESS WIRE
Denodo Integrates NVIDIA NIM Inference Microservices to Accelerate and Optimize AI Capabilities for Enterprises
06/02/2024 - 08:30 AM
BUSINESS WIRE
Denodo Opens ME Regional Head Office in Kingdom of Saudi Arabia to Meet Growing Demand for Data Management and AI
06/02/2024 - 08:30 AM
BUSINESS WIRE
IMFINZI® (durvalumab) is the first and only immunotherapy to show survival benefit in limited-stage small cell lung cancer in global Phase III trial, reducing the risk of death by 27% vs. placebo
06/02/2024 - 08:05 AM
BUSINESS WIRE
Gilead and Arcus Announce Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-line Metastatic Colorectal Cancer
06/02/2024 - 08:00 AM
BUSINESS WIRE
1
2
3
4
5
6
7
8
9
10
11
...
1500
Next »